Published by Coherent Market Insights
Posted on September 14, 2021
Alcoholic hepatitis is a serious, inflammatory condition of the liver caused by excessive alcohol consumption over time. It is often exacerbated by heavy drinking and long-term alcohol use. Due to continuous drinking, some additional complications may occur in body such as cirrhosis, excessive bleeding, and even liver failure. When the liver is harmed, as a result of decades of heavy drinking, it can become inflamed, scarred, and fatty, and eventually may stop working properly. For instance, according to the American Liver Foundation 2017, alcoholic hepatitis affects only a small percentage of heavy drinkers in the U.S. that is not over 35%.
The common symptoms of alcoholic hepatitis include pain and swelling in abdomen, fatigue, weight loss, jaundice, nausea & vomiting, fever, easy bleeding, and bruising.
Request Sample Copy + related graphs of the report@ https://www.coherentmarketinsights.com/insight/request-sample/4485
If the alcoholic hepatitis is mild, stopping consumption of alcohol may help in reversing the disease. Changing the diet, which include intake of low-sodium foods along with diuretics and vitamin supplements, could be another form of treatment. Medication that reduces inflammation in the liver and improves liver function such as corticosteroids (pentoxifylline) may be used to treat alcoholic hepatitis. If the above-mentioned treatments do not work, owing to the disease progression, a liver transplant may be required.
The rising cases of alcohol use and deaths due to alcoholic hepatitis are expected to propel the growth of global alcoholic hepatitis treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2018, 25.1% of adults aged 18 and above had at least one heavy drinking day (five or more drinks for men and four or more drinks for women) in the U.S. Moreover, in 2019, 24,110 people died as a result of alcoholic liver disease in the U.S.
Moreover, increasing product launches and approvals is expected to boost global alcoholic hepatitis treatment market growth. For instance, on December 16, 2020, Durect Corporation announced that DUR-928 was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholic hepatitis. Durect is a biopharmaceutical company dedicated to transforming the treatment of acute organ injury and chronic liver diseases through the development of novel, potentially lifesaving therapies. DUR-928, Durect’s lead drug candidate, is an endogenous sulfated oxysterol and an epigenetic regulator with a distinct mechanism of action. Epigenetic regulators are compounds that control gene expression patterns without altering the DNA sequence. These factors are expected to support global alcoholic hepatitis treatment market growth over the forecast period.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/4485
Global Alcoholic Hepatitis Treatment Market – Taxonomy
By Drug Class:
By Distribution Channel:
By Region:
Request Here For PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/4485
Competitive landscape
Key players operating in the global alcoholic hepatitis treatment market include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Alkermes plc , Mallinckrodt Pharmaceuticals, Durect Corporation , Novartis AG, Teva Pharmaceutical Industries Ltd., Aventis Pharma Ltd., and Cipla Ltd.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Alcoholic Hepatitis Treatment Market Industry Insights, Trends, Outlook, and Opportunity Analysis, 2021-2028 appeared first on Gatorledger.
Alcoholic hepatitis is a serious, inflammatory condition of the liver caused by excessive alcohol consumption over time. It is often exacerbated by heavy drinking and long-term alcohol use. Due to continuous drinking, some additional complications may occur in body such as cirrhosis, excessive bleeding, and even liver failure. When the liver is harmed, as a result of decades of heavy drinking, it can become inflamed, scarred, and fatty, and eventually may stop working properly. For instance, according to the American Liver Foundation 2017, alcoholic hepatitis affects only a small percentage of heavy drinkers in the U.S. that is not over 35%.
The common symptoms of alcoholic hepatitis include pain and swelling in abdomen, fatigue, weight loss, jaundice, nausea & vomiting, fever, easy bleeding, and bruising.
Request Sample Copy + related graphs of the report@ https://www.coherentmarketinsights.com/insight/request-sample/4485
If the alcoholic hepatitis is mild, stopping consumption of alcohol may help in reversing the disease. Changing the diet, which include intake of low-sodium foods along with diuretics and vitamin supplements, could be another form of treatment. Medication that reduces inflammation in the liver and improves liver function such as corticosteroids (pentoxifylline) may be used to treat alcoholic hepatitis. If the above-mentioned treatments do not work, owing to the disease progression, a liver transplant may be required.
The rising cases of alcohol use and deaths due to alcoholic hepatitis are expected to propel the growth of global alcoholic hepatitis treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2018, 25.1% of adults aged 18 and above had at least one heavy drinking day (five or more drinks for men and four or more drinks for women) in the U.S. Moreover, in 2019, 24,110 people died as a result of alcoholic liver disease in the U.S.
Moreover, increasing product launches and approvals is expected to boost global alcoholic hepatitis treatment market growth. For instance, on December 16, 2020, Durect Corporation announced that DUR-928 was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholic hepatitis. Durect is a biopharmaceutical company dedicated to transforming the treatment of acute organ injury and chronic liver diseases through the development of novel, potentially lifesaving therapies. DUR-928, Durect’s lead drug candidate, is an endogenous sulfated oxysterol and an epigenetic regulator with a distinct mechanism of action. Epigenetic regulators are compounds that control gene expression patterns without altering the DNA sequence. These factors are expected to support global alcoholic hepatitis treatment market growth over the forecast period.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/4485
Global Alcoholic Hepatitis Treatment Market – Taxonomy
By Drug Class:
By Distribution Channel:
By Region:
Request Here For PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/4485
Competitive landscape
Key players operating in the global alcoholic hepatitis treatment market include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Alkermes plc , Mallinckrodt Pharmaceuticals, Durect Corporation , Novartis AG, Teva Pharmaceutical Industries Ltd., Aventis Pharma Ltd., and Cipla Ltd.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Alcoholic Hepatitis Treatment Market Industry Insights, Trends, Outlook, and Opportunity Analysis, 2021-2028 appeared first on Gatorledger.
Explore more articles in the Research Reports category
